You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Dow
Merck
Express Scripts
Colorcon
Baxter
AstraZeneca

Last Updated: October 24, 2020

DrugPatentWatch Database Preview

Details for Patent: 8,367,685

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Which drugs does patent 8,367,685 protect, and when does it expire?

Patent 8,367,685 protects OPSUMIT and is included in one NDA.

This patent has thirty-one patent family members in twenty-three countries.

Summary for Patent: 8,367,685
Title:Stable pharmaceutical compositions comprising a pyrimidine-sulfamide
Abstract: Stable pharmaceutical compositions include the compound of the below formula, or pharmaceutically acceptable salts, solvates, hydrates or morphological forms thereof: ##STR00001##
Inventor(s): Adesuyi; Charles Tokunbo (Swindon, GB), Holman; Lovelace (Arlesheim, CH), Lambert; Olivier (Spechbach-le-Haut, FR), Lithgow; Bruce Hamilton (Bath, GB)
Assignee: Actelion Pharmaceuticals, Ltd. (Allschwil, CH)
Application Number:12/388,142
Patent Claim Types:
see list of patent claims
Composition; Compound; Dosage form; Use;

Drugs Protected by US Patent 8,367,685

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Actelion Pharms Ltd OPSUMIT macitentan TABLET;ORAL 204410-001 Oct 18, 2013 RX Yes Yes   Start Trial   Start Trial Y METHOD OF TREATING PULMONARY ARTERIAL HYPERTENSION BY ADMINISTERING A PHARMACEUTICAL COMPOSITION COMPRISING MACITENTAN AND A POLYSORBATE, WHERIN THE POLYSORBATE REPRESENTS 0.1 TO 1% OF THE WEIGHT OF SAID PHARMACEUTICAL COMPOSITION   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 8,367,685

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
PCT/EP2005/009775Sep 15, 2005

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Dow
Merck
McKinsey
Harvard Business School
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.